肿瘤血管生成的分子影像学研究进展

陈敏; 魏玲格; 刘晓梅; 陈敏; 魏玲格; 刘晓梅

doi:10.3760/cma.j.issn.1673-4114.2012.02.001

[1]

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285(21): 1182-1186.

[2]

Mazeron R, Bourhis J, Deutsch E. Angiogenesis: all a radiation oncologist should know. Cancer Radiother, 2008, 12(1): 50-60.

[3]

张国鹏, 兰晓莉, 何勇, 等. ⁹⁹Tc^m-亚锡葡庚糖酸钠结合GGC序列监测基因治疗的实验研究.中华核医学杂志, 2011, 31(2): 128-133.

[4]

Wang P, Zhen H, Zhang J, et al. Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog, 2011[2012-01-10]. http://onlinelibrary.wiley.com/doi/10.1002/mc.20829/abstract;jsessionid=719EB7C1790AF3BC30D13D2BF55D8814.d03t02. [published online ahead of print July 14, 2011].

[5]

赵新明, 戴萌, 刘亚丽, 等. ⁹⁹Tc^m-survivin mRNA反义肽核酸制备及荷瘤裸鼠基因显像研究.中华核医学杂志, 2011, 31(5): 339-343.

[6]

Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci, 2009, 14: 3094-3110.

[7]

杨明福, 李前伟.肿瘤血管内皮生长因子受体核素显像研究现状.国际放射医学核医学杂志, 2010, 34(1): 19-22.

[8]

Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled ⁹⁹Tc^m-HYNIC-VEGF. Eur J Nucl Med Mol Imaging, 2006, 33(7): 841-848.

[9]

黄定德, 李前伟, 刘广元, 等. ⁹⁹Tc^m标记多肽VEGF125-136及其生物学分布.第三军医大学学报, 2007, 29(17): 1660-1662.

[10]

Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med, 2007, 13(4): 504-509.

[11]

von Wallbrunn A, Höltke C, Zühlsdorf M, et al. In vivo imaging of integrin α_νβ₃ expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging, 2007, 34(5): 745-754.

[12]

Liu S. Radiolaboled muhimeric cyclic RGD peptides as integrin α_νβ₃ targeted radiotracers for tumor imaging. Mol Pharm, 2006, 3(5): 472-487.

[13]

余子璘, 贾兵, 刘昭飞, 等. ⁹⁹Tc^m标记RGD环肽四聚体在神经胶质瘤裸鼠模型中的显像研究.中华核医学杂志, 2009, 29(2): 103-108.

[14]

李玲, 胡漫, 于金明, 等.非小细胞肺癌⁹⁹Tc^m-HL91 SPECT乏氧显像中HL91摄取程度与乏氧诱导因子1α和血管内皮生长因子表达的关系.中华肿瘤杂志, 2009, 31(9): 669-673.

[15]

Bourgeois M, Rajerison H, Guerard F, et al. Contribution of[⁶⁴Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical[¹⁸F]-MISO—a selected review. Nucl Med Rev Cent East Eur, 2011, 14(2): 90-95.

[16]

Grönroos T, Bentzen L, Marjamaki P, et al. Comparison of the biodistribution of two hypoxia markers[¹⁸F]FETNIM and[¹⁸F] FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging, 2004, 31(4): 513-520.

[17]

Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol, 2006, 186(5): 1423-1430.

[18]

Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by α_νβ₃-targeted magnetic resonance imaging. Nat Med, 1998, 4(5): 623-626.

[19]

Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging, 2002, 15(3):233-240.

[20]

Palmowski M, Huppert J, Ladewig G, et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther, 2008, 7(1): 101-109.

[21]

Peng L, Liu R, Andrei M, et al. In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α₄β₁ integrin. Mol Cancer Ther, 2008, 7(2): 432-437.